Fig. 1 | Neuropsychopharmacology

Fig. 1

From: Differential contributions of striatal dopamine D1 and D2 receptors to component processes of value-based decision making

Fig. 1

Task setup and systemic treatment with DA receptor (ant)agonists). a Behavioral task. b Infusion sites included in the analysis. c Effects of systemic treatment with the DA D1 receptor antagonist SCH23390 (0, 0.02 or 0.04 mg/kg) and agonist SKF82958 (0, 0.2 or 0.4 mg/kg) on the behavioral measures of task performance. d Effects of systemic treatment with the DA D1 receptor antagonist SCH23390 (0, 0.02 or 0.04 mg/kg) and agonist SKF82958 (0, 0.2 or 0.4 mg/kg) on the computational modeling parameters. e Effects of systemic treatment with the DA D2 receptor antagonist raclopride (0, 0.1 or 0.2 mg/kg) and agonist quinpirole (0, 0.02 or 0.08 mg/kg) on the behavioral measures of task performance. f Effects of systemic treatment with the DA D2 receptor antagonist raclopride (0, 0.1 or 0.2 mg/kg) and agonist quinpirole (0, 0.02 or 0.08 mg/kg) on the computational modeling parameters. The statistical range is denoted as: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001. n = 24 rats for SCH23390, SKF82958, and quinpirole, and n = 18 rats for raclopride

Back to article page